Clinical Trial Search

Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05

Primary: Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast) — 2200; 2230…

Primary: Geometric Mean Titers Of Subjects After Each Vaccination Of a Cell-Culture Derived H7N9c Monovalent Vaccine, Hemagglutination Inhibition Assay (Day 43) — 5; 5; 5; 5.05…

Primary: Maintenance of Negative Pressure — 22.2 hours

Primary: Area Under Curve (AUC) Time Frame: Predose, 0.5,1,1.5,2,3,5,8,12,24,48,72hours Post-dose — 37256; 37206 mcg*hr/mL — p=<0.05

Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 24 h at Steady State — 1182.084; 1110.095; 1070.909 ng*h/mL

Primary: Proportion of Participants Who Discontinue Study — 7.1 Percentage of Participants

Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615 — 17950000; 933800 nanogram*hour per milliliter

Primary: Pharmacodynamic Effect: The Platelet Inhibition Effect of Clopidogrel at the Various Times on Day 7 (0-24 Hours) (at Steady State) — 1853.58; 1892.84 percent…

Primary: Percentage BOLD (Blood-oxygen-level Dependent Contrast Imaging) Signal From Baseline at 2 Weeks — 3; 2 percentage change of BOLD

Primary: Unsolicited Adverse Event Reports — 3; 4 Unsolicited Adverse Event Reports

Primary: Adjusted Mean Change From Baseline in Evaporative Sensitivity Pain Response of Hypersensitive Tooth on a Visual Analogue Scale (VAS) Immediately Post Application of 5%…

Primary: Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran. — 1220; 1160; 893 ng∙h/mL

Primary: Dose Limiting Toxicity Assessment and Maximum Tolerated Dose Determination — 0.0; 0.0; 50.0; 0.0 percentage of participants

Primary: OZ439 Cmax — 1300; 1490; 1240; 1120 ng/mL